Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Funding

    European Joint Programme on Rare Diseases

    Funding programme, Funded by: Horizon 2020, Submission deadline: 16/02/2021
    https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/european-joint-programme-rare-diseases
  • Press release - 11/01/2021

    CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
  • Event - 12/07/2021 - 14/07/2021

    Future Insight Days

    online, Kongress/Symposium
    https:////www.gesundheitsindustrie-bw.de:443/en/event/future-insight-days
  • Event - 23/02/2021 - 25/02/2021

    Life-on-Chip Conference

    online, Registration deadline: 17/02/2021
    https:////www.gesundheitsindustrie-bw.de:443/en/event/life-chip-conference
  • Funding

    JOINT TRANSNATIONAL CALL 2021

    Funding programme, Funded by: Horizon 2020, Submission deadline: 04/03/2021
    https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/joint-transnational-call-2021
  • Press release - 07/01/2021

    CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV

    Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
  • Infection control - 07/01/2021 Elektronenmikroskopische Aufnahme von pink gefärbten Staphylococcus aureus Bakterien auf einer lila gefärbten Zelloberfläche.

    Gene accordions as potential markers for pathogenic properties

    Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/news/gene-accordions-potential-markers-pathogenic-properties
  • Press release - 22/12/2020

    Voluntary or compulsory? New evidence on motivation for anti-Covid-19 policies

    A study by the University of Konstanz shows that voluntary motivation to comply with anti-Covid-19 policies is relatively high in Germany, but can be undermined by enforcement - The consequence of this finding differs depending on the policy.

    https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/voluntary-or-compulsory-new-evidence-motivation-anti-covid-19-policies
  • Press release - 09/12/2020

    Combatting cancer with biological circuits

    The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project "InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods". Di Ventura will use the 2 Million Euros to develop a novel cancer treatment based on molecular methods from synthetic biology.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/combatting-cancer-biological-circuits
  • Funding

    INNO4COV-19 Project

    Funding programme, Funded by: Horizon 2020, Submission deadline: 31/03/2021
    https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/inno4cov-19-project
  • Digitalisation in Medicine - 08/12/2020 Bild-1_Druckergehaeuse.jpg

    DiHeSys takes steps towards application

    Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/dihesys-takes-steps-towards-application
  • Press release - 07/12/2020

    One for all

    AI-based evaluation of medical imaging data usually requires a specially developed algorithm for each task. Scientists from the German Cancer Research Center (DKFZ) have now presented a new method for configuring self-learning algorithms for a large number of different imaging datasets – without the need for specialist knowledge or very significant computing power.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/one-all
  • Development of the genomDE genome database - 04/12/2020 national-cancer-institute-to8o0bqOA6Q-unsplash.jpg

    Whole genome sequencing for diagnosing rare diseases

    Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
  • Press release - 03/12/2020

    HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model

    New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-erreicht-meilenstein-mit-dem-nachweis-von-sicherheit-und-wirksamkeit-der-mkk4-inhibition-im-model-fuer-fortgeschritt
  • Press release - 01/12/2020

    Novel vaccine trial to activate T-cell responses against SARS-CoV-2

    A Phase I clinical trial using a self-developed vaccine against SARS-CoV-2 was initiated today at the University Hospital of Tübingen. In contrast to the currently evaluated vaccine candidates against COVID-19, the vaccine CoVAC1, developed by the Department of Immunology (Director Prof. Hans-Georg Rammensee) at the University of Tübingen, aims specifically at the induction of a T-cell-mediated immune response against SARS-COV-2.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/Novel-vaccine-trial-to-activate-T-cell-responses-against-SARS-CoV-2
  • Press release - 26/11/2020

    New mechanism of action: A small-molecule degrades a cancer-promoting protein by gluing it into filaments

    “Molecular glue degraders” are a new class of cancer drugs, which “glue” cancer growth-promoting proteins directly to the molecular machinery of a cell’s disposal system, leading to the subsequent degradation of the cancer-driving proteins and anti-tumor activity. Scientists from Heidelberg and USA have now deciphered another mechanism whereby a small molecule can degrade a cancer protein.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-mechanism-action-small-molecule-degrades-cancer-promoting-protein-gluing-it-filaments
  • New method for analysing blood samples - 26/11/2020 Bildschirmfoto_2020-10-30_um_11.46.25.png

    Personalised therapy monitoring for malignant melanomas

    Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
  • Press release - 17/11/2020

    The Long Road to Dementia

    The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/long-road-dementia
  • Press release - 16/11/2020

    European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/european-commission-announces-tomorrow-it-will-authorize-agreement-curevac-supply-405-million-doses-mrna-based-covid-19-vaccine
  • Funding

    COSME

    Funding programme, Funded by: Horizon 2020, Submission deadline: 19/01/2021
    https:////www.gesundheitsindustrie-bw.de/en/database/funding/cosme
  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Press release - 09/11/2020

    Making sense of what you see in biomedical images

    Sometimes an image is just an image. Sometimes it gives those who can read it correctly a deeper insight into what they can see. In many scientific disciplines, the key to extracting meaningful information from large three-dimensional images, obtained from X-ray tomography or optical microscopy, is segmentation, a tedious and time-consuming – and therefore error-prone – task if done manually.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/making-sense-what-you-see-biomedical-images
  • Funding

    TRANSVAC: New Vaccines Faster

    Funding programme, Funded by: Horizon2020, Submission deadline: 15/12/2020
    https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/transvac-new-vaccines-faster
  • Press release - 09/11/2020

    Infection diagnostics 3.0: Faster thanks to nanopore sequencing

    To ensure that sepsis patients receive appropriate antibiotics as quickly as possible, Fraunhofer IGB researchers have developed a diagnostic procedure that uses high-throughput sequencing of blood samples and delivers results much faster than conventional culture-based techniques. Thanks to the latest single-molecule sequencing techniques, this process has now been further improved so that pathogens can be identified after just a few hours.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/infection-diagnostics-30-faster-thanks-nanopore-sequencing

Page 1 / 108

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 108
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search